TY - JOUR
T1 - Late T cell–mediated rejection may contribute to poor outcomes in adolescents and young adults with liver transplantation
AU - Takeda, Masahiro
AU - Sakamoto, Seisuke
AU - Irie, Rie
AU - Uchida, Hajime
AU - Shimizu, Seiichi
AU - Yanagi, Yusuke
AU - Abdelwahed, Mohamed Sami
AU - Fukuda, Akinari
AU - Kasahara, Mureo
N1 - Publisher Copyright:
© 2020 Wiley Periodicals LLC
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Although poor long-term graft survival in LT in AYA is recognized, detailed epidemiological data are still lacking. L-TCMR may have poor outcomes. This study aimed to provide a detailed, epidemiological assessment of the association between AYA age and rejection. L-TCMR was defined in this study as TCMR with central vein or perivenular inflammation occurring later than 3 months after LT. A total of 342 patients who survived for at least 3 months after LT between 2005 and 2015 were enrolled. The AYA group (10-24 years) was compared with the C group (less than 10 years), and the incidence and outcomes of L-TCMR were analyzed. In total, 342 patients had LT; 38 of these were AYA with the mean follow-up period of 6.7 years. A total of 304 patients in C group had a mean follow-up period of 6.3 years (P =.28). The incidence of L-TCMR in AYA group was significantly higher than in C group (15.8% vs 4.6%, P =.006). The time to L-TCMR after LT was significantly shorter in AYA group (P =.01). Neither patient survival nor the incidence of non-adherence differed significantly between the groups (P =.18 and P =.89). The number of additional immunosuppressants after L-TCMR was significantly higher in the AYA group (P =.04). A high incidence of L-TCMR was observed in AYA group irrespective of non-adherence. AYA patients with L-TCMR should be followed carefully due to the poor results of post-treatment biopsy and the need for intensive immunosuppressive therapy.
AB - Although poor long-term graft survival in LT in AYA is recognized, detailed epidemiological data are still lacking. L-TCMR may have poor outcomes. This study aimed to provide a detailed, epidemiological assessment of the association between AYA age and rejection. L-TCMR was defined in this study as TCMR with central vein or perivenular inflammation occurring later than 3 months after LT. A total of 342 patients who survived for at least 3 months after LT between 2005 and 2015 were enrolled. The AYA group (10-24 years) was compared with the C group (less than 10 years), and the incidence and outcomes of L-TCMR were analyzed. In total, 342 patients had LT; 38 of these were AYA with the mean follow-up period of 6.7 years. A total of 304 patients in C group had a mean follow-up period of 6.3 years (P =.28). The incidence of L-TCMR in AYA group was significantly higher than in C group (15.8% vs 4.6%, P =.006). The time to L-TCMR after LT was significantly shorter in AYA group (P =.01). Neither patient survival nor the incidence of non-adherence differed significantly between the groups (P =.18 and P =.89). The number of additional immunosuppressants after L-TCMR was significantly higher in the AYA group (P =.04). A high incidence of L-TCMR was observed in AYA group irrespective of non-adherence. AYA patients with L-TCMR should be followed carefully due to the poor results of post-treatment biopsy and the need for intensive immunosuppressive therapy.
UR - http://www.scopus.com/inward/record.url?scp=85084072846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084072846&partnerID=8YFLogxK
U2 - 10.1111/petr.13708
DO - 10.1111/petr.13708
M3 - Article
C2 - 32333637
AN - SCOPUS:85084072846
SN - 1397-3142
VL - 24
JO - Pediatric Transplantation
JF - Pediatric Transplantation
IS - 4
M1 - e13708
ER -